Related Experiment Video

Updated: May 13, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

Myocardial 'no-reflow' prevention

Michael Magro1, Tirza Springeling, Robert Jan van Geuns

  • 1Chief Department of Cardiology, Erasmus MC, Thorax center, 's Gravendijkwal 230, Rotterdam, The Netherlands.

Current Vascular Pharmacology
|March 20, 2013
PubMed

Insights

Preventing myocardial no-reflow after ST-segment elevation myocardial infarction (STEMI) is vital for better outcomes. Strategies focus on preserving microvascular function and timely interventions during primary percutaneous coronary intervention (PPCI).

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Microvascular Medicine

Background:

  • Myocardial no-reflow occurs in 5-50% of ST-segment elevation myocardial infarction (STEMI) patients despite successful primary percutaneous coronary intervention (PPCI).
  • No-reflow predicts larger infarct size and increased short- and long-term mortality.
  • Preventing no-reflow is critical for improving STEMI patient prognosis.

Purpose of the Study:

  • To review current strategies for preventing myocardial no-reflow during STEMI treatment.
  • To discuss pharmacological and mechanical interventions aimed at improving microvascular perfusion.
  • To highlight the importance of early intervention and risk factor management.

Main Methods:

  • Review of major clinical trials and studies on no-reflow prevention.
  • Analysis of strategies including glycaemic control, statin use, reduced ischaemic time, and specific PPCI techniques.
  • Discussion of pharmacological agents and mechanical interventions.

Main Results:

  • Optimal glycaemic control and statin therapy reduce no-reflow risk in high-risk patients (e.g., diabetics).
  • Minimizing door-to-balloon times and employing intracoronary GP IIb/IIIa antagonists and aspiration thrombectomy improve myocardial perfusion.
  • These interventions are associated with better clinical outcomes in major trials.

Conclusions:

  • Preventing myocardial no-reflow is a key therapeutic goal in STEMI management.
  • A multi-faceted approach combining risk factor modification and optimized PPCI techniques is essential.
  • Further research into novel therapeutic options continues to advance no-reflow prevention strategies.

More Related Videos

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...